$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000155837021003815 Filed on March 31, 2021

Income Statement

Concept	2020 Q4	2020	2019 Q4
Revenue	$13.75M	$45.60M	$11.13M
YoY Change	23.54%	24.49%	23.79%
Cost Of Revenue	$4.280M	$14.59M	$3.560M
YoY Change	20.22%	38.57%	125.32%
Gross Profit	$9.470M	$31.01M	$7.570M
YoY Change	25.1%	18.81%	2.16%
Gross Profit Margin	68.87%	67.99%	68.01%
Selling, General & Admin	$15.81M	$61.17M	$14.33M
YoY Change	10.33%	10.03%	-1.71%
% of Gross Profit	166.95%	197.28%	189.3%
Research & Development	$17.96M	$64.11M	$23.62M
YoY Change	-23.96%	-21.17%	-5.71%
% of Gross Profit	189.65%	206.77%	312.02%
Depreciation & Amortization	$950.0K	$2.300M	$860.0K
YoY Change	10.47%	21.05%	16.22%
% of Gross Profit	10.03%	7.42%	11.36%
Operating Expenses	$33.77M	$125.3M	$37.95M
YoY Change	-11.01%	-8.5%	-4.24%
Operating Profit	-$24.30M	-$94.27M	-$30.38M
YoY Change	-20.01%	-14.93%	-26.29%
Interest Expense	$3.950M	-$8.580M	-$2.530M
YoY Change	-256.13%	-7.94%	-21.43%
% of Operating Profit
Other Income/Expense, Net		-$8.579M	$0.00
YoY Change		-193.67%
Pretax Income	-$20.35M	-$102.8M	-$32.96M
YoY Change	-38.26%	1.17%	-4.82%
Income Tax	$140.0K	$136.0K
% Of Pretax Income
Net Earnings	-$5.300M	-$46.53M	-$15.49M
YoY Change	-65.78%	16.43%	-37.74%
Net Earnings / Revenue	-38.55%	-102.03%	-139.17%
Basic Earnings Per Share
Diluted Earnings Per Share	-$66.41K	-$646.2K	-$259.6K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$233.4M	$233.4M	$136.9M
YoY Change	70.49%	70.49%	64.74%
Cash & Equivalents	$233.4M	$233.4M	$136.9M
Short-Term Investments			$0.00
Other Short-Term Assets	$6.700M	$6.700M	$4.100M
YoY Change	63.41%	63.41%	-79.29%
Inventory	$1.404M	$1.400M	$857.0K
Prepaid Expenses
Receivables	$23.93M	$19.30M	$13.54M
Other Receivables	$800.0K	$800.0K	$900.0K
Total Short-Term Assets	$266.2M	$261.6M	$156.3M
YoY Change	70.33%	67.37%	40.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.92M	$32.40M	$12.43M
YoY Change	-4.1%	-4.42%	3.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$17.60M	$17.60M	$11.10M
YoY Change	58.56%	58.56%
Other Assets	$1.013M	$2.700M	$1.158M
YoY Change	-12.52%	-84.75%	319.57%
Total Long-Term Assets	$67.26M	$67.20M	$70.17M
YoY Change	-4.14%	-4.14%	135.58%
TOTAL ASSETS
Total Short-Term Assets	$266.2M	$261.6M	$156.3M
Total Long-Term Assets	$67.26M	$67.20M	$70.17M
Total Assets	$333.4M	$328.8M	$226.4M
YoY Change	47.25%	45.23%	60.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.41M	$20.40M	$22.90M
YoY Change	-50.17%	-10.92%	-33.04%
Accrued Expenses	$45.39M	$22.10M	$25.40M
YoY Change	78.7%	42.58%	55.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$5.300M	$5.300M	$7.200M
YoY Change	-26.39%	-26.39%	-62.3%
Total Short-Term Liabilities	$51.76M	$48.00M	$45.62M
YoY Change	13.47%	5.26%	-17.98%
LONG-TERM LIABILITIES
Long-Term Debt	$59.00M	$59.00M	$82.40M
YoY Change	-28.4%	-28.4%	36.42%
Other Long-Term Liabilities	$1.949M	$24.80M	$2.136M
YoY Change	-8.75%	-3.88%	-59.01%
Total Long-Term Liabilities	$1.949M	$83.80M	$2.136M
YoY Change	-8.75%	-22.55%	-59.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$51.76M	$48.00M	$45.62M
Total Long-Term Liabilities	$1.949M	$83.80M	$2.136M
Total Liabilities	$136.4M	$228.5M	$153.9M
YoY Change	-11.36%	14.14%	26.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$482.8M		-$436.2M
YoY Change	10.67%		10.08%
Common Stock	$95.00K		$74.00K
YoY Change	28.38%		27.59%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$100.3M	$100.3M	$26.22M
YoY Change
Total Liabilities & Shareholders Equity	$333.4M	$328.8M	$226.4M
YoY Change	47.25%	45.23%	60.59%

Cashflow Statement

Concept	2020 Q4	2020	2019 Q4
OPERATING ACTIVITIES
Net Income	-$5.300M	-$46.53M	-$15.49M
YoY Change	-65.78%	16.43%	-37.74%
Depreciation, Depletion And Amortization	$950.0K	$2.300M	$860.0K
YoY Change	10.47%	21.05%	16.22%
Cash From Operating Activities	-$20.48M	-$83.68M	-$25.05M
YoY Change	-18.24%	-11.88%	13.04%
INVESTING ACTIVITIES
Capital Expenditures	-$900.0K	$1.926M	-$890.0K
YoY Change	1.12%	-17.87%	-42.21%
Acquisitions
YoY Change
Other Investing Activities	-$670.0K	-$4.040M	$1.200M
YoY Change	-155.83%	-116.26%	-92.03%
Cash From Investing Activities	-$1.560M	-$7.164M	$310.0K
YoY Change	-603.23%	-135.65%	-97.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$45.78M
YoY Change		121.38%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	37.01M	172.4M	27.15M
YoY Change	36.32%	17.51%	-1706.51%
NET CHANGE
Cash From Operating Activities	-20.48M	-83.68M	-25.05M
Cash From Investing Activities	-1.560M	-7.164M	310.0K
Cash From Financing Activities	37.01M	172.4M	27.15M
Net Change In Cash	14.97M	81.56M	2.410M
YoY Change	521.16%	13.52%	-123.33%
FREE CASH FLOW
Cash From Operating Activities	-$20.48M	-$83.68M	-$25.05M
Capital Expenditures	-$900.0K	$1.926M	-$890.0K
Free Cash Flow	-$19.58M	-$85.61M	-$24.16M
YoY Change	-18.96%	-12.02%	17.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y3M29D
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y10M2D
CY2020	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74027425
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	94877492
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1341167
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2028-12-31
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-35366
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5157386
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Gansevoort Street
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	9th Floor
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10014
CY2020	dei	City Area Code CityAreaCode	781
CY2020	dei	Local Phone Number LocalPhoneNumber	652-4500
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	173878853
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	233351000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136858000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	19349000
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13539000
CY2020Q4	us-gaap	Inventory Net InventoryNet	1404000
CY2019Q4	us-gaap	Inventory Net InventoryNet	857000
CY2020Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	744000
CY2019Q4	us-gaap	Due From Other Related Parties Current DueFromOtherRelatedPartiesCurrent	865000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6723000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4133000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	261571000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	156252000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11923000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12433000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20487000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	21480000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	1645000
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	16574000
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	17566000
CY2019Q4	us-gaap	Long Term Investments LongTermInvestments	11148000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7377000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1013000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1158000
CY2020Q4	us-gaap	Assets Assets	328834000
CY2019Q4	us-gaap	Assets Assets	226422000
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	40674000
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	35451000
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	1042000
CY2020Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	0
CY2019Q4	fbio	Due To Related Parties Interest Expenses Current DueToRelatedPartiesInterestExpensesCurrent	92000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	136000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2020Q4	us-gaap	Notes Payable Current NotesPayableCurrent	0
CY2019Q4	us-gaap	Notes Payable Current NotesPayableCurrent	7220000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1849000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1784000
CY2020Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	27000
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5300000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	47959000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45616000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	8323000
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	5086000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	51677000
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	77436000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	22891000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	23712000
CY2020Q4	fbio	Partner Company Note Payable Long Term PartnerCompanyNotePayableLongTerm	7359000
CY2019Q4	fbio	Partner Company Note Payable Long Term PartnerCompanyNotePayableLongTerm	4990000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1949000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2136000
CY2020Q4	us-gaap	Liabilities Liabilities	131835000
CY2019Q4	us-gaap	Liabilities Liabilities	153890000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2019Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2020Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1341167
CY2019Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2020Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94877492
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	74027425
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	95000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	74000
CY2020Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	0
CY2019Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	251337
CY2020Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	0
CY2019Q4	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	500000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	583000000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	461874000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-482760000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-436234000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	100338000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	26215000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	96661000
CY2019Q4	us-gaap	Minority Interest MinorityInterest	46317000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196999000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	72532000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	328834000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	226422000
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44531000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34921000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1068000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1708000
CY2020	us-gaap	Revenues Revenues	45599000
CY2019	us-gaap	Revenues Revenues	36629000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14594000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10532000
CY2020	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	61275000
CY2019	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	75236000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2834000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6090000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61166000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	55590000
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	139869000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	147448000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-94270000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-110819000
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	1518000
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	2559000
CY2020	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	15326000
CY2019	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	11849000
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1189000
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	27000
CY2020	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	6418000
CY2019	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0
CY2020	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	18476000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8579000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9159000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-102849000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-101660000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2019	us-gaap	Profit Loss ProfitLoss	-101660000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56459000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61700000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-46526000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-39960000
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.43
CY2019	us-gaap	Income Loss From Continuing Operations Per Basic And Diluted Share IncomeLossFromContinuingOperationsPerBasicAndDilutedShare	-1.86
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-0.78
CY2019	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic And Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicAndDilutedShare	-1.13
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.73
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	72005181
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54711838
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19743000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	13188000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	123000
CY2019	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	20247000
CY2019	fbio	Adjustments To Additional Paid In Capital Preferred Stock Issued For At Market Offering AdjustmentsToAdditionalPaidInCapitalPreferredStockIssuedForAtMarketOffering	788000
CY2019	fbio	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	-5307000
CY2019	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2559000
CY2019	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	78607000
CY2019	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	29785000
CY2019	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	90000
CY2019	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	888000
CY2019	fbio	Common Shares Issuable For Subordinated Note Financial Interest Expenses CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses	500000
CY2019	fbio	Common Shares Issued For Subordinated Note Financial Interest Expenses CommonSharesIssuedForSubordinatedNoteFinancialInterestExpenses	1474000
CY2019	fbio	Common Shares Issuable For Opus Interest Expenses In Value CommonSharesIssuableForOpusInterestExpensesInValue	281000
CY2019	fbio	Common Shares Issued For Opus Interest Expenses In Value CommonSharesIssuedForOpusInterestExpensesInValue	381000
CY2019	fbio	Common Shares Issued For Opus Debt In Value CommonSharesIssuedForOpusDebtInValue	500000
CY2019	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	4849000
CY2019	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	61700000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-39960000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	72532000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	72532000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	13451000
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	18000
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	253000
CY2020	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	45827000
CY2020	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6515000
CY2020	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	72000
CY2020	fbio	Stock Issued During Period Value Preferred Stock StockIssuedDuringPeriodValuePreferredStock	-35543000
CY2020	fbio	Adjustments To Additional Paid In Capital Subsidiary Public Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering	53749000
CY2020	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	70988000
CY2020	fbio	Adjustments To Additional Paid In Capital Preferred Stock Offering Net AdjustmentsToAdditionalPaidInCapitalPreferredStockOfferingNet	7074000
CY2020	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	349000
CY2020	us-gaap	Dividends Common Stock DividendsCommonStock	237000
CY2020	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	13000
CY2020	fbio	Partner Companys Exercise Of Options For Cash PartnerCompanysExerciseOfOptionsForCash	13000
CY2020	fbio	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	1216000
CY2020	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	46000
CY2020	fbio	Common Shares Issuable For Subordinated Note Financial Interest Expenses CommonSharesIssuableForSubordinatedNoteFinancialInterestExpenses	1317000
CY2020	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants In Conjunction With Debt Instrument AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsInConjunctionWithDebtInstrument	4419000
CY2020	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	56459000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-46526000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	196999000
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2019	us-gaap	Profit Loss ProfitLoss	-101660000
CY2020	us-gaap	Depreciation Depreciation	2280000
CY2019	us-gaap	Depreciation Depreciation	1922000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	49000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000
CY2020	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	5622000
CY2019	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3321000
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	697000
CY2019	us-gaap	Paid In Kind Interest PaidInKindInterest	0
CY2020	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	1420000
CY2019	us-gaap	Cost Of Goods And Services Sold Amortization CostOfGoodsAndServicesSoldAmortization	1174000
CY2020	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1625000
CY2019	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1558000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	13451000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	13188000
CY2020	fbio	Common Shares Issuable For Service CommonSharesIssuableForService	18000
CY2019	fbio	Common Shares Issuable For Service CommonSharesIssuableForService	0
CY2020	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	46000
CY2019	fbio	Issuance Of Subsidiaries Common Stock For Research And Development Expenses IssuanceOfSubsidiariesCommonStockForResearchAndDevelopmentExpenses	90000
CY2020	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	0
CY2019	fbio	Issuance Of Common Stock For Interest Expense IssuanceOfCommonStockForInterestExpense	500000
CY2020	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	1317000
CY2019	fbio	Common Stock Issued For Interest Expenses CommonStockIssuedForInterestExpenses	1474000
CY2020	fbio	Common Stock Issuable For Notes Interest Expense CommonStockIssuableForNotesInterestExpense	0
CY2019	fbio	Common Stock Issuable For Notes Interest Expense CommonStockIssuableForNotesInterestExpense	281000
CY2020	fbio	Common Stock Issued For Notes Interest Expense CommonStockIssuedForNotesInterestExpense	0
CY2019	fbio	Common Stock Issued For Notes Interest Expense CommonStockIssuedForNotesInterestExpense	381000
CY2020	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	1189000
CY2019	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	27000
CY2020	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	6418000
CY2019	fbio	Change In Fair Value Of Short Term Investments ChangeInFairValueOfShortTermInvestments	0
CY2020	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	0
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	18476000
CY2020	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	2788000
CY2019	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	6000000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5859000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8141000
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	547000
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	179000
CY2020	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-121000
CY2019	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-1230000
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2590000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1798000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-145000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	882000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	6522000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2095000
CY2020	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	0
CY2019	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-149000
CY2020	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-1042000
CY2019	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	8000
CY2020	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-92000
CY2019	us-gaap	Increase Decrease In Due To Other Related Parties Current IncreaseDecreaseInDueToOtherRelatedPartiesCurrent	-5000
CY2020	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	136000
CY2019	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	0
CY2020	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1388000
CY2019	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-1365000
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-187000
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	749000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-83682000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-94961000
CY2020	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4038000
CY2019	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4650000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1926000
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2345000
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1200000
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2400000
CY2020	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	0
CY2019	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	5000000
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0
CY2019	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	22604000
CY2020	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	0
CY2019	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	1201000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7164000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	7008000
CY2020	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0
CY2019	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	13089000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7164000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20097000
CY2020	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	6515000
CY2019	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	2559000
CY2020	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	70000
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2020	fbio	Payments For Costs Related To Purchase Of Treasury Stock PaymentsForCostsRelatedToPurchaseOfTreasuryStock	2000
CY2019	fbio	Payments For Costs Related To Purchase Of Treasury Stock PaymentsForCostsRelatedToPurchaseOfTreasuryStock	0
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	39075000
CY2019	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	6038000
CY2020	fbio	Payment Of Costs Related To Issuance Of Series Preferred Stock PaymentOfCostsRelatedToIssuanceOfSeriesPreferredStock	3535000
CY2019	fbio	Payment Of Costs Related To Issuance Of Series Preferred Stock PaymentOfCostsRelatedToIssuanceOfSeriesPreferredStock	578000
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47509000
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20680000
CY2020	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1658000
CY2019	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	427000
CY2020	fbio	Proceeds From Issuance Of Series Preferred Stock For At Market Offering ProceedsFromIssuanceOfSeriesPreferredStockForAtMarketOffering	0
CY2019	fbio	Proceeds From Issuance Of Series Preferred Stock For At Market Offering ProceedsFromIssuanceOfSeriesPreferredStockForAtMarketOffering	812000
CY2020	fbio	Payment Of Cost Related To Issuance Of Preferred Stock At Market Offering PaymentOfCostRelatedToIssuanceOfPreferredStockAtMarketOffering	0
CY2019	fbio	Payment Of Cost Related To Issuance Of Preferred Stock At Market Offering PaymentOfCostRelatedToIssuanceOfPreferredStockAtMarketOffering	24000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	253000
CY2019	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	123000
CY2020	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	349000
CY2019	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	0
CY2020	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	237000
CY2019	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	0
CY2020	fbio	Proceeds From Partner Companies Sale Of Stock ProceedsFromPartnerCompaniesSaleOfStock	57729000
CY2019	fbio	Proceeds From Partner Companies Sale Of Stock ProceedsFromPartnerCompaniesSaleOfStock	86180000
CY2020	fbio	Payment Of Costs Related To Partner Companies Sale Of Stock PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock	4049000
CY2019	fbio	Payment Of Costs Related To Partner Companies Sale Of Stock PaymentOfCostsRelatedToPartnerCompaniesSaleOfStock	6671000
CY2020	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	72570000
CY2019	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	30526000
CY2020	fbio	Payment Of Cost Related To Subsidiaries At The Market Offering PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering	1498000
CY2019	fbio	Payment Of Cost Related To Subsidiaries At The Market Offering PaymentOfCostRelatedToSubsidiariesAtTheMarketOffering	741000
CY2020	fbio	Proceeds From Partner Company S Preferred Stock Offering ProceedsFromPartnerCompanySPreferredStockOffering	8000000
CY2019	fbio	Proceeds From Partner Company S Preferred Stock Offering ProceedsFromPartnerCompanySPreferredStockOffering	0
CY2020	fbio	Payment Of Costs Related To Partner Company S Preferred Stock Offering PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering	913000
CY2019	fbio	Payment Of Costs Related To Partner Company S Preferred Stock Offering PaymentOfCostsRelatedToPartnerCompanySPreferredStockOffering	0
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	13000
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	13000
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2020	fbio	Installment Payment Related To Intangible Asset InstallmentPaymentRelatedToIntangibleAsset	500000
CY2019	fbio	Installment Payment Related To Intangible Asset InstallmentPaymentRelatedToIntangibleAsset	0
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	172410000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	146714000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	81564000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	71850000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153432000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	81582000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153432000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	8204000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	5444000
CY2020	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	617000
CY2019	us-gaap	Interest Expense Related Party InterestExpenseRelatedParty	456000
CY2020	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	2000
CY2019	fbio	Settlement Of Restricted Shares Units Into Common Stock SettlementOfRestrictedSharesUnitsIntoCommonStock	2000
CY2020	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	0
CY2019	fbio	Issue Of Common Stock For Acquiring License Value IssueOfCommonStockForAcquiringLicenseValue	164000
CY2020	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	0
CY2019	fbio	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	888000
CY2020	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	4419000
CY2019	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2020	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	500000
CY2019	fbio	Common Shares Issued For2017 Subordinated Note Financing Interest Expense CommonSharesIssuedFor2017SubordinatedNoteFinancingInterestExpense	0
CY2020	fbio	Common Shares Issued For2019 Notes CommonSharesIssuedFor2019Notes	0
CY2019	fbio	Common Shares Issued For2019 Notes CommonSharesIssuedFor2019Notes	500000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	31000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	187000
CY2020	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	7472000
CY2019	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	4734000
CY2020	fbio	Partner Company Previous Paid Offering Cost PartnerCompanyPreviousPaidOfferingCost	0
CY2019	fbio	Partner Company Previous Paid Offering Cost PartnerCompanyPreviousPaidOfferingCost	833000
CY2020	fbio	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	1216000
CY2019	fbio	Reclassification Of Warrants From Liability To Equity ReclassificationOfWarrantsFromLiabilityToEquity	0
CY2020	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	0
CY2019	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	69000
CY2020	fbio	Unpaid Partner Companys At Market Offering Cost UnpaidPartnerCompanysAtMarketOfferingCost	84000
CY2019	fbio	Unpaid Partner Companys At Market Offering Cost UnpaidPartnerCompanysAtMarketOfferingCost	0
CY2020	fbio	Unpaid Partner Companys Preferred Stock Offering Cost UnpaidPartnerCompanysPreferredStockOfferingCost	13000
CY2019	fbio	Unpaid Partner Companys Preferred Stock Offering Cost UnpaidPartnerCompanysPreferredStockOfferingCost	0
CY2020	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	13000
CY2019	fbio	Unpaid Debt Offering Cost UnpaidDebtOfferingCost	26000
CY2020	fbio	Unpaid At Market Offering Cost UnpaidAtMarketOfferingCost	30000
CY2019	fbio	Unpaid At Market Offering Cost UnpaidAtMarketOfferingCost	6000
CY2020	fbio	Unpaid Preferred Offering Cost UnpaidPreferredOfferingCost	0
CY2019	fbio	Unpaid Preferred Offering Cost UnpaidPreferredOfferingCost	153000
CY2020	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	0
CY2019	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	1350000
CY2020	fbio	Retirement Of Preferred Stock RetirementOfPreferredStock	70000
CY2019	fbio	Retirement Of Preferred Stock RetirementOfPreferredStock	0
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2020	fbio	Expenses Related To Sales Returns ExpensesRelatedToSalesReturns	1300000
CY2019	fbio	Expenses Related To Sales Returns ExpensesRelatedToSalesReturns	2900000
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	16600000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	233351000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	136858000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1645000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	16574000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	234996000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	153432000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000
CY2020	fbio	Allowance For Sales Returns AllowanceForSalesReturns	4600000
CY2019	fbio	Allowance For Sales Returns AllowanceForSalesReturns	5400000
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1236000
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1153000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6701000
CY2019Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6683000
CY2020Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	5007000
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	17566000
CY2019Q4	fbio	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset And Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetAndLiabilityValue	11175000
CY2019	us-gaap	Proceeds From Sale Of Equity Method Investments ProceedsFromSaleOfEquityMethodInvestments	13089000
CY2019	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	13089000
CY2019Q4	fbio	Deconsolidation Fair Value DeconsolidationFairValue	11148000
CY2019Q4	fbio	Net Liabilities Deconsolidated NetLiabilitiesDeconsolidated	13177000
CY2019	fbio	Deconsolidation Non Controlling Interest Share DeconsolidationNonControllingInterestShare	4849000
CY2019	fbio	Deconsolidation Write Off Of Fees DeconsolidationWriteOffOfFees	1000000
CY2019	us-gaap	Deconsolidation Gain Or Loss Amount DeconsolidationGainOrLossAmount	18476000
CY2019Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	4215000
CY2020Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	518000
CY2019Q4	fbio	Accrued Research And Development Expense Manufacturing AccruedResearchAndDevelopmentExpenseManufacturing	1017000
CY2020Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	461000
CY2019Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	361000
CY2020Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	600000
CY2019Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	0
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18689000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	16919000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6766000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4486000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11923000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12433000
CY2020	us-gaap	Depreciation Depreciation	2300000
CY2019	us-gaap	Depreciation Depreciation	1900000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	1189000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet	-1216000
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	6418000
CY2020Q4	fbio	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset And Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetAndLiabilityValue	17566000
CY2018Q4	fbio	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset And Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetAndLiabilityValue	10905000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	-9914000
CY2019	fbio	Disposal Of National DisposalOfNational	-991000
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1 FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1	11148000
CY2019	fbio	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Change In Fair Value Of Convertible Notes FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisChangeInFairValueOfConvertibleNotes	27000
CY2019Q4	fbio	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Asset And Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisAssetAndLiabilityValue	11175000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2800000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6100000
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2834000
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6090000
CY2020Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	10869000
CY2019Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	8391000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1188000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1259000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29262000
CY2020Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	153120000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-56459000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	96661000
CY2019	us-gaap	Cost Maintenance CostMaintenance	25000
CY2020	us-gaap	Cost Maintenance CostMaintenance	50000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	18606000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9934000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3977000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2557000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7377000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1417000
CY2019	us-gaap	Finitelived Intangible Assets Acquired1 FinitelivedIntangibleAssetsAcquired1	7134000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1174000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7377000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1420000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	25399000
CY2020Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	1949000
CY2019Q4	fbio	Deferred Rent And Long Term Lease Abandonment Non Current DeferredRentAndLongTermLeaseAbandonmentNonCurrent	2136000
CY2020Q4	fbio	Total Other Long Term Liabilities And Partner Company Note Payable Long Term TotalOtherLongTermLiabilitiesAndPartnerCompanyNotePayableLongTerm	9308000
CY2019Q4	fbio	Total Other Long Term Liabilities And Partner Company Note Payable Long Term TotalOtherLongTermLiabilitiesAndPartnerCompanyNotePayableLongTerm	7126000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1286000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1019000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1019000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1019000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1019000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	595000
CY2020Q4	fbio	Finite Lived Intangible Assets Net Excluding Assets That Has Not Been Placed In Service FiniteLivedIntangibleAssetsNetExcludingAssetsThatHasNotBeenPlacedInService	5957000
CY2020Q4	fbio	Intangible Assets Not Yet Placed In Service IntangibleAssetsNotYetPlacedInService	8672000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	60000000
CY2019Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	89742000
CY2020Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8323000
CY2019Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	5086000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	51677000
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	84656000
CY2020	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2018-09-14
CY2020Q4	us-gaap	Cash Cash	13000000.0
CY2020	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	9704000
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	5622000
CY2020	us-gaap	Interest Expense Debt InterestExpenseDebt	15326000
CY2019	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	8528000
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3321000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	11849000
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2682000
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2320000
CY2019Q4	fbio	Minority Interest Equity Share MinorityInterestEquityShare	108017000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-61700000
CY2019Q4	us-gaap	Minority Interest MinorityInterest	46317000
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19216795
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18293739
CY2020	fbio	Common Stock Increase Decrease In Shares Authorized CommonStockIncreaseDecreaseInSharesAuthorized	50000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94877492
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	74027425
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2019	fbio	Class Of Warrant Or Right Granted Weighted Average Intrinsic Value ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue	39000
CY2019	fbio	Class Of Warrant Or Right Number Of Shares Forfeited ClassOfWarrantOrRightNumberOfSharesForfeited	73009
CY2019	fbio	Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue	0
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2741180
CY2019Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.19
CY2019Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	111000
CY2019	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P2Y8M23D
CY2020	fbio	Class Of Warrant Or Right Number Of Shares Granted ClassOfWarrantOrRightNumberOfSharesGranted	1849450
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13451000
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13188000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1285501
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	3.75
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y11M4D
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	125000
CY2019	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.18
CY2019	fbio	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodIntrinsicValue	173750
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1410501
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	4.30
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	684752
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100000
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.18
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	257011
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.57
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1053490
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	5.02
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	647482
CY2018Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2754189
CY2018Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.28
CY2018Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	0
CY2018	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P3Y5M26D
CY2019	fbio	Class Of Warrant Or Right Number Of Shares Granted ClassOfWarrantOrRightNumberOfSharesGranted	60000
CY2019	fbio	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	1.92
CY2019	fbio	Class Of Warrant Or Right Forfeited Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice	5.65
CY2020	fbio	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	3.14
CY2020	fbio	Class Of Warrant Or Right Granted Weighted Average Intrinsic Value ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue	101000
CY2020	fbio	Class Of Warrant Or Right Number Of Shares Forfeited ClassOfWarrantOrRightNumberOfSharesForfeited	9
CY2020	fbio	Class Of Warrant Or Right Forfeited Weighted Average Exercise Price ClassOfWarrantOrRightForfeitedWeightedAverageExercisePrice	3.00
CY2020	fbio	Class Of Warrant Or Right Forfeited Weighted Average Intrinsic Value ClassOfWarrantOrRightForfeitedWeightedAverageIntrinsicValue	2
CY2020Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4590621
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	3.17
CY2020Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	607848
CY2020	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P4Y10M6D
CY2020	fbio	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	4430621
CY2020	fbio	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	3.21
CY2020	fbio	Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue	452848
CY2020	fbio	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife	P4Y9M18D
CY2014Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P15Y
CY2014Q4	us-gaap	Operating Lease Expense OperatingLeaseExpense	2500000
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24700000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	20500000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3200000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	3200000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	3246000
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	3199000
CY2020	us-gaap	Sublease Income SubleaseIncome	1873000
CY2019	us-gaap	Sublease Income SubleaseIncome	1876000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	593000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	801000
CY2020	us-gaap	Lease Cost LeaseCost	1966000
CY2019	us-gaap	Lease Cost LeaseCost	2124000
CY2020	fbio	Lessee Lease Portfolio And Other Supplemental Lease Information LesseeLeasePortfolioAndOtherSupplementalLeaseInformation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company’s operating leases, under the adoption of ASC Topic 842<i style="font-style:italic;">, Leases</i>:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,958)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,001)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 634</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.7</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:62.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table>
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	2958000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	3001000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	634000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y8M12D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y3M18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.063
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.062
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3353000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3461000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3233000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3193000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3244000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	17028000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	33512000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	8772000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	24740000
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000.0
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	2100000
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	500000
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	400000
CY2020Q4	us-gaap	Dividends Receivable DividendsReceivable	13061000
CY2019Q4	us-gaap	Dividends Receivable DividendsReceivable	7589000
CY2020Q4	fbio	Dividends Payable Receivable Current DividendsPayableReceivableCurrent	0
CY2019Q4	fbio	Dividends Payable Receivable Current DividendsPayableReceivableCurrent	0
CY2020	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4000000
CY2019	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4000000
CY2020	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2019	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	136000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.0013
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	203900000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	152295000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	125657000
CY2020Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	20628000
CY2019Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	17077000
CY2020Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	415000
CY2019Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	449000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	14732000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13280000
CY2020Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7306000
CY2019Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7454000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1570000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	1810000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	16326000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	12716000
CY2020Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	54000
CY2019Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	58000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	168223000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	11967000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	10994000
CY2020Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	6050000
CY2019Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	6280000
CY2020Q4	fbio	Deferred Tax Liabilities Gain Loss On Deconsolidation Of Caelum DeferredTaxLiabilitiesGainLossOnDeconsolidationOfCaelum	4804000
CY2019Q4	fbio	Deferred Tax Liabilities Gain Loss On Deconsolidation Of Caelum DeferredTaxLiabilitiesGainLossOnDeconsolidationOfCaelum	2879000
CY2020Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	1113000
CY2019Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	1835000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	1075000
CY2019Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	716000
CY2020Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	41000
CY2019Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	0
CY2020Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	1455000
CY2019Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	0
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	215897000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	179217000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	203930000
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.11
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.12
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.04
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.03
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2020	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.01
CY2019	fbio	Effective Income Tax Rate Reconciliation Provision For Return EffectiveIncomeTaxRateReconciliationProvisionForReturn	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2020	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0
CY2019	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.03
CY2020	fbio	Effective Income Tax Rate Reconciliation Deconsolidation Of Caelum EffectiveIncomeTaxRateReconciliationDeconsolidationOfCaelum	0
CY2019	fbio	Effective Income Tax Rate Reconciliation Deconsolidation Of Caelum EffectiveIncomeTaxRateReconciliationDeconsolidationOfCaelum	-3
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.35
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.36
CY2020	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.01
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	35700000
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020	us-gaap	Revenues Revenues	45599000
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14594000
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17384000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	64109000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	43782000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8579000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	136000
CY2020	us-gaap	Profit Loss ProfitLoss	-102985000
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14629000
CY2020Q4	fbio	Tangible Assets Net TangibleAssetsNet	314205000
CY2020Q4	us-gaap	Assets Assets	328834000
CY2019	us-gaap	Revenues Revenues	36629000
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10532000
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	17120000
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	81326000
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	38470000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9159000
CY2019	us-gaap	Profit Loss ProfitLoss	-101660000
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	7377000
CY2019Q4	fbio	Tangible Assets Net TangibleAssetsNet	219045000
CY2019Q4	us-gaap	Assets Assets	226422000
CY2020	fbio	Number Of Marketed Products NumberOfMarketedProducts	5
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44531000
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34921000
CY2020	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1068000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	1708000
CY2020	us-gaap	Revenues Revenues	45599000
CY2019	us-gaap	Revenues Revenues	36629000
CY2020	fbio	Product Revenue Constrained In Prior Period ProductRevenueConstrainedInPriorPeriod	1400000
CY2019	fbio	Product Revenue Constrained In Prior Period ProductRevenueConstrainedInPriorPeriod	0

Files In Submission

Name	View Source	Status
0001558370-21-003815-index-headers.html	Edgar Link	pending
0001558370-21-003815-index.html	Edgar Link	pending
0001558370-21-003815.txt	Edgar Link	pending
0001558370-21-003815-xbrl.zip	Edgar Link	pending
fbio-20201231.xsd	Edgar Link	pending
fbio-20201231x10k.htm	Edgar Link	pending
fbio-20201231x10k_htm.xml	Edgar Link	completed
fbio-20201231xex21d1.htm	Edgar Link	pending
fbio-20201231xex23d1.htm	Edgar Link	pending
fbio-20201231xex31d1.htm	Edgar Link	pending
fbio-20201231xex31d2.htm	Edgar Link	pending
fbio-20201231xex32d1.htm	Edgar Link	pending
fbio-20201231xex32d2.htm	Edgar Link	pending
fbio-20201231xex4d3.htm	Edgar Link	pending
fbio-20201231_cal.xml	Edgar Link	unprocessable
fbio-20201231_def.xml	Edgar Link	unprocessable
fbio-20201231_lab.xml	Edgar Link	unprocessable
fbio-20201231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2020 Q4 Form 10-K Financial Statement

#000155837021003815 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2020 Q4 Form 10-K Financial Statement

#000155837021003815 Filed on March 31, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio